本文關(guān)鍵詞： 卒中后抑郁 養(yǎng)血清腦顆粒 蒙哥馬利-艾森貝格抑郁量表 漢密爾頓抑郁量表　出處：《南京中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：研究目的:探索養(yǎng)血清腦顆粒治療卒中后輕中度抑郁的臨床療效及安全性,為未來研究提供參考。研究方法:采用多中心、自身前后對照的研究方法,對符合卒中后抑郁診斷標(biāo)準(zhǔn)(輕中度)的神經(jīng)內(nèi)科門診/住院病人,在腦梗死及基礎(chǔ)病治療基礎(chǔ)上給予養(yǎng)血清腦顆�？诜�(4g/次,3次/日,共12周)。分別在治療前(第0日)、治療2周、6周、12周后評定其MADRS評分、HAMD17評分及HAMA評分,并分別在治療前及治療12周后評定其NIHSS評分,記錄服藥期間不良反應(yīng)。采用SPSS 21.0統(tǒng)計軟件進(jìn)行數(shù)據(jù)資料分析,比較治療前后各量表評分變化,以及不良反應(yīng)發(fā)生情況。結(jié)果:本研究共納入患者32例,完成研究31例,其中男性21例,女性10例,平均年齡66.19±7.95歲,平均病程4.28±2.62周;失訪1例。養(yǎng)血清腦顆粒治療2周、6周、12周后MADRS 評分分別為 14.936±4.195、12.097±2.737、8.936±1.263,HAMD17 評分分別為13.839±3.226、11.548±2.307、7.968±1.303,HAMA 評分分別為 8.258±2.113、7.548±2.111、6.452±2.047。以上指標(biāo)均較第0日有明顯不同,差異具有統(tǒng)計學(xué)意義(P0.05);治療12周后基于MADRS評分及HAMD17評分減分率判定的有效率分別為70.97%、67.74%。治療12周后NIHSS評分與第0日比較有改善且差異具有統(tǒng)計學(xué)意義(P0.05)。完成試驗的31例病人均無不良反應(yīng)出現(xiàn)。結(jié)論:初步表明養(yǎng)血清腦顆粒治療卒中后輕中度抑郁有效,且安全性良好。本研究的樣本含量及研究方法使結(jié)論具有局限性,需大樣本、設(shè)計更為嚴(yán)謹(jǐn)?shù)脑囼炦M(jìn)一步驗證。
[Abstract]:Objective: to explore the clinical efficacy and safety of Yangxuannao granule in the treatment of mild to moderate depression after stroke, and to provide a reference for future research. The outpatients / inpatients of neurology who met the diagnostic criteria of post-stroke depression (mild to moderate) were given Yangxuanao granule 3 times a day on the basis of the treatment of cerebral infarction and basic diseases. The MADRS score, HAMD17 score and HAMA score were evaluated before and after treatment (day 0, 2 weeks and 6 weeks and 12 weeks later, respectively), and their NIHSS scores were evaluated before and after 12 weeks of treatment. Adverse reactions during medication were recorded. Data were analyzed by SPSS 21. 0 statistical software. The scores of each scale before and after treatment were compared. Results: 32 patients were included in this study, and 31 patients completed the study. There were 21 males and 10 females with an average age of 66.19 鹵7.95 years and an average course of 4.28 鹵2.62 weeks. The MADRS scores were 14.936 鹵4.195 鹵12.097 鹵2.737 鹵8.936 鹵1.263 HMD17, 13.839 鹵3.2266.548 鹵2.307 鹵7.968 鹵1.303 Hama, 8.258 鹵2.113 鹵7.548 鹵2.111 鹵6.452 鹵47.7, respectively. After 12 weeks of treatment, the effective rate based on MADRS score and HAMD17 score reduction rate were 70.97 and 67.745.After 12 weeks of treatment, the NIHSS score was improved compared with that on day 0, and the difference was statistically significant (P 0.05). Conclusion: Yangxuannao granule is effective in treating mild and moderate depression after stroke. The safety is good. The conclusion of this study is limited by sample content and research method, and needs to be further verified by a more rigorous design test.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R743.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 慕英;;帕羅西汀聯(lián)合養(yǎng)血清腦顆粒治療卒中后抑郁的臨床療效[J];中國實用神經(jīng)疾病雜志;2014年20期

2 李曉鶴;;腦卒中后抑郁患者腦源性神經(jīng)營養(yǎng)因子檢測及其影響因素[J];檢驗醫(yī)學(xué)與臨床;2014年12期

3 潘東;甘井山;;養(yǎng)血清腦顆粒聯(lián)合鹽酸舍曲林治療腦卒中后抑郁的臨床觀察[J];中國藥房;2014年20期

4 李曉鶴;;腦卒中后抑郁患者腦源性神經(jīng)營養(yǎng)因子與炎癥因子的相關(guān)性[J];檢驗醫(yī)學(xué)與臨床;2014年10期

5 楊忠;;肌肉松弛訓(xùn)練聯(lián)合音樂療法在腦卒中后抑郁患者中應(yīng)用價值[J];安徽醫(yī)藥;2014年04期

6 宋飛;季華;;文拉法辛與選擇性5-HT再攝取抑制劑治療腦卒中后抑郁的療效和安全性Meta分析[J];醫(yī)學(xué)研究雜志;2014年04期

7 周勇;龍明;冉宏;;西酞普蘭聯(lián)合養(yǎng)血清腦顆粒治療腦卒中后抑郁的臨床觀察[J];中國藥房;2014年12期

8 毛一清;晏玉奎;;被動音樂療法對腦卒中后抑郁患者的臨床療效觀察[J];中國現(xiàn)代醫(yī)生;2013年30期

9 尹俊雄;曾憲容;任泗昌;程媛媛;程遠(yuǎn);潘福瓊;;高壓氧治療卒中后抑郁隨機對照試驗的系統(tǒng)評價[J];中國循證醫(yī)學(xué)雜志;2013年10期

10 劉[?溥;張吟秋;朱緋;王凡;姜梅玲;龔莉萍;;化痰活血解郁法治療卒中后抑郁狀態(tài)臨床觀察[J];吉林中醫(yī)藥;2013年08期

，

本文編號：1554957